Login:   Password:     Retrieve login/password
Quick links

2019 AETA & CETA/ACTE Joint Annual Convention
October 24-26, 2019
Cheyenne Mountain Resort
Colorado Springs, Colorado

Other conferences of interest

Association News

Register now for the 2019 AETA & CETA/ACTE Joint Annual Convention in Colorado Springs, Colorado, October 24–26, 2019!

Register online or download the printable registration form and return it by mail (AETA, 1800 South Oak Street, Suite 100, Champaign, IL 61820) or by fax (217-398-4119).

If you are registering online and need to register a companion or register as a technician working with an AETA member, please contact Morgan Montgomery at morganm@assochq.org. You will not be able to register either of these two attendee types online.

The meeting will take place at the Cheyenne Mountain Resort. Be sure to make your hotel reservations by September 30 to get the convention rate. Make your reservations online here or by calling 1-800-588-0250. Please refer to the AETA-CETA/ACTE room block when making reservations by phone.

Cheyenne Mountain Resort offers airport transfer from the Colorado Springs Airport to the hotel for $20 each way. You can make your arrival shuttle reservation when you book your hotel room. If you make your hotel reservation online, you must call the hotel (1-800-588-0250) to reserve an arrival airport shuttle. To arrange an airport transfer for your return flight, you can call the front desk an hour before you are ready to depart.

More information about the meeting, companion tours, pre-conference events, hotel information, and registration links can be found on the meeting website.

If you have any questions or concerns, please do not hesitate to contact us via email at aeta@assochq.org or by phone at 217-398-2217.

We look forward to seeing you in Colorado Springs!

Legality of Compounded Estradiol for Embryo Transfer

The AABP office has received questions from members regarding the legality of using compounded estradiol products in cattle for embryo transfer protocols. AABP has also been in discussion with the FDA about the use of compounded estradiol products in food animals. Compounding from approved drugs in animals is only permitted under the narrowly defined conditions outlined in AMDUCA (Section 21 CFR 530.13). To be permitted, extralabel use from compounding of approved animal drugs or approved human drugs must be in compliance with all relevant provisions of 21 CFR 530 (AMDUCA), including the provisions limiting extralabel use to treatment modalities when the health of an animal is threatened or suffering or death may result from failure to treat. The extralabel use regulation also does not provide for compounding from active pharmaceutical ingredients (API or bulk drugs, i.e., the raw chemical) for use in animals. Therefore, it is illegal for veterinarians to use or prescribe compounded estradiol for cattle or any form of estrogenic compounds for production purposes including embryo transfer and synchronization protocols. AABP encourages cattle veterinarians to refrain from administering or prescribing compounded estradiol for the following reasons:

  • AMDUCA only allows for extralabel drug use when the health of an animal is threatened. There is no production allowance, particularly for compounding; therefore, one cannot use human-approved drugs (i.e., ECP, Pfizer) or a different form of an animal-approved drug (i.e., growth-promoting implants) for production purposes.
  • Compounding from a bulk product is specifically prohibited in the AMDUCA regulations.
  • The safety, potency, efficacy, stability, sterility, and disposition of compounded products is unknown. Compounded products do not undergo FDA inspection, potency testing, or efficacy testing. Veterinary compounding pharmacies that also compound for humans are under federal regulation and FDA inspected; however, this only applies to the human side of the compounding operation. Veterinary compounding pharmacies do not have this level of oversight. There is no guarantee of the safety or efficacy of compounded products and the liability for the use of such products falls on the veterinarian in the event of an adverse reaction or violative residue.
  • Because the safety, efficacy, potency, and disposition of the compounded product is not known, it is impossible to assign a withdrawal interval for compounded products.
  • The use of compounded products in food animals places a veterinarian at a risk of professional liability.

The need for estradiol for successful embryo transfer protocols has not been unequivocally established. For example, data from nearly 7,000 collections did not demonstrate a difference when using GnRH in place of estradiol in the protocol. Additional references are available on the Reproduction Committee page of the website. Veterinarians who engage in federally prohibited activities put themselves at risk and also risk the profession’s reputation for appropriate and judicious oversight of pharmaceutical products in our cattle patients. This is especially of concern when using an unapproved and illegally manufactured hormone product. AABP Newsletter 5 May 2019

Please contact the Fred Gingrich at fred@aabp.org with any questions.

AETA Video

Global Genetic Improvement Through Embryo Technology

Small Ruminant Embryo Transfer Training Video

Click the image below to watch the video (AETA members only). A DVD is available for purchase

Unified Login for User Accounts
AETA has implemented the Unified Login technology to relieve members of having to remember multiple login/password combinations. Wherever you see this icon, you are able to use the same login information!